ArticleTranslational cancer research2019

The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer-a commentary on the E5103 randomized phase III clinical study.

Giandomenico Roviello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.